COMBINED FORMULATION OF LEUKOTRIENE ANTAGONIST AND EPINASTINE

摘要

The present invention relates to a combined formulation of a leukotriene antagonist and epinastine containing a leukotriene antagonist and epinastine as active ingredients, comprising a pharmaceutical unit, wherein any one of the two active ingredients have an environment separated from that of the other, and a preparation method thereof. The combined formulation has an excellent dissolution rate and bioavailability of a leukotriene antagonist. Furthermore, the two active ingredients synergically reduce eosinophils or inhibit airway hyperresponsiveness, and thus the combined formulation can be very useful for preventing or treating bronchial asthma.